Oligomerix to Present at AAIC 2020 Conference on Small Molecule Inhibitor of Tau Self-Association

Oligomerix Appoints William Erhardt, M.D., as Chief Medical Officer

Oligomerix Announces Appointment of Robert Foerster, Former Pfizer Executive, as Chief Financial Officer

Oligomerix Presents Preclinical Data at TAU2020 Global Conference for Small Molecule Inhibitor of Tau Self-Association

Oligomerix to Present at BIO CEO & Investor Conference, Tau2020 Global Conference

Newly Discovered Drug Is Able To Inhibit Neurotoxic Tau Oligomers In Brains, Paving The Way For A Potential Cure for Alzheimer

Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data

Oligomerix Awarded $2.18 Million SBIR Grant for Tau Oligomer Inhibitor for Alzheimer’s Disease and Related Disorders

Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies

Oligomerix to Participate in the NIH Innovation Zone at 2019 BIO International Convention